Last reviewed · How we verify
Lantus (insulin glargine)
Lantus is a long-acting basal insulin that binds to insulin receptors to lower blood glucose by promoting glucose uptake into cells and inhibiting hepatic glucose production.
Lantus is a long-acting basal insulin that binds to insulin receptors to lower blood glucose by promoting glucose uptake into cells and inhibiting hepatic glucose production. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Lantus (insulin glargine) |
|---|---|
| Also known as | Lantus |
| Sponsor | Sanofi |
| Drug class | Long-acting basal insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Insulin glargine is a recombinant human insulin analog engineered with amino acid substitutions to provide a prolonged, peakless duration of action (up to 24 hours). It mimics the body's basal insulin secretion by activating insulin receptors on muscle, fat, and liver cells, facilitating glucose uptake and storage while suppressing gluconeogenesis and glycogenolysis. This sustained glucose-lowering effect helps maintain stable blood glucose levels throughout the day and night in diabetic patients.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes (NA)
- Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes (PHASE2)
- iGlarLixi CGM Study in Chinese T2D Individuals After OADs (PHASE4)
- Effect of Topical Insulin on Healing Rate of Pemphigus Lesions (PHASE2)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes (PHASE3)
- Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes (PHASE4)
- A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lantus (insulin glargine) CI brief — competitive landscape report
- Lantus (insulin glargine) updates RSS · CI watch RSS
- Sanofi portfolio CI